Here, we report an innovative nanocapsule-based drug delivery system that synergizes its own biological effect (stimulation of GLP-1 release) and that of the encapsulated bioactive molecule (exenatide) as an alternative strategy for the treatment of T2DM and hepatic steatosis via an oral route. Here, GCG is linked to type 2 diabetes mellitus.